NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Announces Custom Hybridoma Development - Leveraging our world-class peptide synthesis expertise and antibody production experience, AnaSpec, EGT Group is pleased to offer high quality custom monoclonal antibody services to the research community and pharmaceutical industry
AnaSpec Announces Custom Hybridoma Development

 

NewswireTODAY - /newswire/ - Fremont, CA, United States, 2012/10/08 - Leveraging our world-class peptide synthesis expertise and antibody production experience, AnaSpec, EGT Group is pleased to offer high quality custom monoclonal antibody services to the research community and pharmaceutical industry.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

We have the capabilities to raise monoclonal antibodies to difficult antigens, including peptide sequences that contain post-translational modifications.

• Consultation in peptide antigen design;
• Peptide antigens with post-translational modifications can be made;
• Flexible protocol and schedule based on customer’s needs;
• Immunization time frame of four to eight weeks;
• Up-to-date report and customer validation following each project step;
• Accessible technical support with expertise in antibody production;
• Resources and technical proficiency to work with customer on unconventional projects.

Our routine production of monoclonal antibodies is comprised of three phases (Phase I – III). Customers only pay for each phase that is successfully completed. Phase IV, large-scale production of monoclonal antibodies, is optional and available as a stand-alone purchase. Details of each phase are shown below.

Phase I: Antigen Preparation and Immunization (~8-9 weeks);
• Design and production of synthetic peptide antigens with or without modifications;
• Site-directed conjugation of peptide antigens to carrier proteins (e.g., KLH and BSA) for flexibility in antigen presentation;
• Preparation of peptide and protein antigens with adjuvants for immunization;
• Initial and boost immunizations of at least four animals;
• Serum separation, ELISA testing and customer consultation before proceeding to Phase II.

Phase II: Fusion and Selection of Parental Clones (~3 weeks)
• Splenocytes are harvested for cell fusion from mice with the highest titer;
• Clones of fused cells are expanded and screened by ELISA;
• Supernatants, from up to ten ELISA-positive parental clones, are shipped to customer for further antibody testing in immunoassays;
• The best parental clones (up to three) are chosen for Phase III after customer consultation.

Phase III: Subcloning and selection of Single Clones (~3 weeks)
• Parental clones are sub-cloned by limiting dilution to isolate single clones;
• Isotype determination of single clones – IgG subtype guaranteed single clones are expanded and screened by ELISA;
• Single clones with high specificity (e.g., phospho vs. non-phospho) and antibody titer will be expanded and cryopreserved;
• Three hybridomas, and their supernatants, will be shipped to customer.

Phase IV: Large-Scale Production of Monoclonal Antibodies (optional) (~3-6weeks)
• In vivo ascites or in vitro Bioreactor antibody production is available;
• Purification of monoclonal antibodies by affinity chromatography using Protein G or with the immunizing peptide antigen;
• ELISA and SDS-PAGE are done to validate the purity of the antibody;
• AnaSpec offers a range of production scales with flexible cost adjustment.

In addition to our custom services, AnaSpec, EGT Group offers popular catalog monoclonal antibodies such as the anti-amyloid (1-40) and (1-42) antibodies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Announces Custom Hybridoma Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Custom Hybridoma |
Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Novotech Awarded by Frost & Sullivan for Global Biotech Clinical Trials Excellence in APAC
Ipsen Receives CHMP Negative Opinion for Palovarotene as A Treatment for Fibrodysplasia Ossificans Progressiva in E.U
Ipsen Presents Positive Results from the Pivotal Phase III NAPOLI 3 Trial Evaluating An Investigational Regimen of Onivyde®
SCHOTT Opens First Facility in U.S. to Increase Capabilities and Capacity for Development and Manufacturing of Diagnostics and Life Sciences Products
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease with Treatments for Several Pediatric Liver Diseases
Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers
Ipsen Demonstrates Commitment to Innovation in Neuroscience At 12th World Congress for Neurorehabilitation (WCNR)
BASF Pharma Solutions Excipient Accepted into FDA Pilot Program for Novel Excipients
Digital Technologies Drive Growth Across the Biomanufacturing Value Chain Finds Frost & Sullivan
DSM Starts Construction of Large Scale Production Facility for its Novel Methane-reducing Feed Additive for Ruminants, Bovaer® in Dalry, Scotland
Collaboration Between Drug and Medical Food Manufacturers to Boost Market Growth Says Frost & Sullivan
Parexel Recognized by Frost & Sullivan with 2022 Global Customer Value Leadership Award
Ipsen’s Global Natural History Study of Fibrodysplasia Ossificans Progressiva Shows Debilitating Impact of the Disease Over An Individual’s Lifetime
BASF and Evonik Partner to Reduce the Environmental Footprint of the Feed and Animal Protein Industries
Rely+On Virkon from LANXESS Effective Against Monkeypox Virus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Limelon Advertising, Co.





 
  ©2005-2023 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)